Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Active, not recruiting
Aragon Pharmaceuticals, Inc.
Phase 1/Phase 2
2010-07-26
The purpose of this study is to assess the safety and activity of ARN-509 in men with
advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1
of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase
2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of
ARN-509.
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Active, not recruiting
Aragon Pharmaceuticals, Inc.
Phase 3
2013-10-14
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men
with high-risk non-metastatic castration-resistant prostate cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
